Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review

Evanthia Thomaidou,Eleni Karlafti,Matthaios Didagelos,Kalliopi Megari,Eleni Argiriadou,Karolina Akinosoglou,Daniel Paramythiotis,Christos Savopoulos
DOI: https://doi.org/10.3390/v16030455
2024-03-16
Viruses
Abstract:Acute acalculous cholecystitis (AAC) represents cholecystitis without gallstones, occurring in approximately 5–10% of all cases of acute cholecystitis in adults. Several risk factors have been recognized, while infectious diseases can be a cause of cholecystitis in otherwise healthy people. Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has spread worldwide, leading to an unprecedented pandemic. The virus enters cells through the binding of the spike protein to angiotensin-converting enzyme 2 (ACE2) receptors expressed in many human tissues, including the epithelial cells of the gastrointestinal (GI) tract, and this explains the symptoms emanating from the digestive system. Acute cholecystitis has been reported in patients with COVID-19. The purpose of this review is to provide a detailed analysis of the current literature on the pathogenesis, diagnosis, management, and outcomes of AAC in patients with COVID-19.
virology
What problem does this paper attempt to address?
The paper aims to provide a detailed analysis of the existing literature on the pathogenesis, diagnosis, management, and prognosis of Acute Acalculous Cholecystitis (AAC) in COVID-19 patients. Specifically: 1. **Pathogenesis**: The potential association between COVID-19 infection and AAC is explored, including direct viral invasion of gallbladder epithelial cells, inflammatory response syndrome, and microvascular thrombosis due to a hypercoagulable state. 2. **Diagnosis**: The clinical manifestations, imaging features, and laboratory test results of AAC in COVID-19 patients are summarized. 3. **Management**: Various treatment methods for AAC in COVID-19 patients are discussed, including conservative treatment, percutaneous transhepatic gallbladder drainage (PTGD), and surgical treatment (such as laparoscopic cholecystectomy). 4. **Prognosis**: The prognosis of AAC in COVID-19 patients is analyzed and compared with that of non-COVID-19 patients. Through a comprehensive analysis of these aspects, the paper aims to provide clinicians with a thorough understanding of AAC in COVID-19 patients to facilitate better diagnosis and treatment.